GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Novartis India Ltd

Novartis India: Sale of shares by Novartis AG completed, license agreement signed

BOARD ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 29 Jul 2026, 09:18 PM IST  ·  BSE ID: 72b7c4c1-990b-47e5-b7f3-a1453ec542ef
View Original BSE Filing (PDF)
💡
In Simple Terms
Novartis AG has sold its stake in Novartis India to a consortium, and new licensing and distribution agreements have been approved.
🤖 AI Summary
  • Novartis AG completed the sale of 17,450,680 equity shares in Novartis India Ltd.
  • The transaction was completed on July 29, 2026, as per the February 19, 2026 agreement.
  • Board approved the Tegrital Brand License Deed between Novartis AG and Novartis India.
  • Board approved a distribution agreement with Novartis Pharma Services dated July 29, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Equity Shares Sold
17,450,680
Agreement Date (Sale)
February 19, 2026
Transaction Completion Date
July 29, 2026
Tegrital Brand License Deed Date
July 29, 2026
Distribution Agreement Date
July 29, 2026
🏢 How This Affects the Company
📈
Business Impact
The completion of the sale signifies a change in significant shareholding. The brand license and distribution agreements will define future operational arrangements for specific products.
💰
Financial Impact
The financial impact of the share sale is on the selling entity (Novartis AG) and the acquiring consortium. The licensing and distribution agreements will impact future revenue streams and cost structures for Novartis India.
⚙️
Operational Impact
New management or strategic direction may be implemented by the acquiring consortium. Operational relationships with Novartis AG and Novartis Pharma Services will be governed by the new agreements.
⚠️
Risk Impact
New ownership introduces potential shifts in strategic focus and operational management. The terms of the license and distribution agreements will determine the extent of ongoing collaboration and associated risks.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders regarding these disclosures.
👤
Who Is Affected
All shareholders are affected by the change in significant shareholding and the new business agreements which may influence future company performance.
🔍
Management Signal
The execution of new agreements with Novartis AG and Novartis Pharma Services indicates a continued operational relationship under the new ownership structure.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Details of the acquiring consortium's strategic plans.
First quarterly results post-shareholder change.
Performance of Tegrital brand under new license.
MEDIUM RISK Significant change in shareholding and new business agreements introduce integration and strategic shift risks.
💡 Investor Takeaway
Novartis AG completed the sale of 17,450,680 equity shares in Novartis India Ltd. The company also secured a Tegrital brand license and a new distribution agreement, effective July 29, 2026.
⚖️ Strengths & Concerns

✅ Positives

  • Completion of share sale by Novartis AG to a consortium on July 29, 2026.
  • Approval of Tegrital brand license deed and distribution agreement on July 29, 2026.
❓ Frequently Asked Questions
What transaction was completed by Novartis India on July 29, 2026?
Novartis AG completed the sale of 17,450,680 equity shares in Novartis India to WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners.
What new license agreement did Novartis India approve?
The Board approved the Tegrital Brand License Deed dated July 29, 2026, between Novartis AG and Novartis India.
What distribution agreement was approved by Novartis India's Board?
The Board approved a distribution agreement dated July 29, 2026, executed between Novartis Pharma Services and Novartis India.
When was the agreement for the sale of Novartis India shares entered into?
The agreement for the sale and purchase of Sale Shares in Novartis India Limited was entered into on February 19, 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.